← Leaderboards
Dawn S Chandler
University Of Texas Md Anderson Can Ctr
$5,230,006
Attributed
$5,411,836
Total exposure
8
Grants
6
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $546.4K · FY2007–25$1M$750K$500K$250K$0
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$5,411,836 · 8
By mechanism
R01$3,683,341 · 2
R21$1,473,406 · 4
R03$168,010 · 1
F32$87,079 · 1
Top collaborators
- Ruoning Wang2 shared
Others in their field
Top investigators on “Rna Splicing”
- Rolf Apweiler · European Molecular Biology Laboratory$41,336,566
- Daniel H Geschwind · University Of California Los Angeles$31,650,067
- Stacey Gabriel · Massachusetts Institute Of Technology$30,450,662
- Brenton R Graveley · University Of Connecticut Sch Of Med/Dnt$30,235,936
- Adrian R Krainer · Cold Spring Harbor Laboratory$28,755,040
- George M Church · Harvard University (Medical School)$26,862,961
Research focus
Rna SplicingLengthPhenotypeMouse ModelCellsTumorigenesisPathway InteractionsProteinsPublishingTumorTherapeutic InterventionMutationMalignant NeoplasmsMrna PrecursorGenerationsResponseRhabdomyosarcomaMolecularAlternative SplicingRegulationDesignProtein IsoformsMediatingTumorigenic
Grant awards (27)
Mdm2 Alternative Splicing in DNA Damage and Cancer$464,185
R01 · FY2025 · CA · contact PI
Mdm2 Alternative Splicing in DNA Damage and Cancer$377,997
R01 · FY2024 · CA · contact PI
Mdm2 Alternative Splicing in DNA Damage and Cancer$73,827
R01 · FY2024 · CA · contact PI
Mdm2 Alternative Splicing in DNA Damage and Cancer$63,326
R01 · FY2024 · CA · contact PI
Mdm2 Alternative Splicing in DNA Damage and Cancer$31,249
R01 · FY2024 · CA · contact PI
Mdm2 Alternative Splicing in DNA Damage and Cancer$390,286
R01 · FY2023 · CA · contact PI
Mdm2 Alternative Splicing in DNA Damage and Cancer$65,326
R01 · FY2023 · CA · contact PI
Mdm2 Alternative Splicing in DNA Damage and Cancer$395,173
R01 · FY2022 · CA · contact PI
A new mouse model for testing splice-switching therapies in IGF-driven cancers$77,000
R03 · FY2022 · CA · contact PI
Diversity Supplement R01----Mdm2 Alternative Splicing in DNA Damage and Cancer$70,289
R01 · FY2022 · CA · contact PI
Mdm2 Alternative Splicing in DNA Damage and Cancer$426,202
R01 · FY2021 · CA · contact PI
A new mouse model for testing splice-switching therapies in IGF-driven cancers$91,010
R03 · FY2021 · CA · contact PI
Oncogenic fusion gene FAX-FKHR in driving metabolic reprogramming in alveolar rhabdomyosarcoma$165,300
R21 · FY2020 · CA
Oncogenic fusion gene FAX-FKHR in driving metabolic reprogramming in alveolar rhabdomyosarcoma$198,360
R21 · FY2019 · CA
Targeting insulin receptor splicing for treatment of rhabdomyosarcoma$164,349
R21 · FY2017 · CA · contact PI
Targeting insulin receptor splicing for treatment of rhabdomyosarcoma$196,022
R21 · FY2016 · CA · contact PI
Using TSUNAMI in a sensitized mouse to generate an intermediate SMA model$183,125
R21 · FY2015 · NS · contact PI
Coordinately regulated alternative splicing in DNA damage and cancer$289,653
R01 · FY2014 · CA · contact PI
Using TSUNAMI in a sensitized mouse to generate an intermediate SMA model$219,750
R21 · FY2014 · NS · contact PI
Coordinately regulated alternative splicing in DNA damage and cancer$245,202
R01 · FY2013 · CA · contact PI
Coordinately regulated alternative splicing in DNA damage and cancer$260,853
R01 · FY2012 · CA · contact PI
Coordinately regulated alternative splicing in DNA damage and cancer$260,853
R01 · FY2011 · CA · contact PI
Coordinately regulated alternative splicing in DNA damage and cancer$268,920
R01 · FY2010 · CA · contact PI
SMN2 Silent Mutation Knock-in: New SMA Mouse Model-Better Therapies$189,000
R21 · FY2008 · NS · contact PI
SMN2 Silent Mutation Knock-in: New SMA Mouse Model-Better Therapies$157,500
R21 · FY2007 · NS · contact PI
A Novel RING Finger Protein Implicated in Neoplasia$38,931
F32 · FY2003 · CA
A Novel RING Finger Protein Implicated in Neoplasia$48,148
F32 · FY2002 · CA